Is Regeneron (Finally) Getting Back on Track? [The Motley Fool]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: The Motley Fool
The FDA has approved Dupixent for moderate to severe eczema, and it has accepted the company's resubmission of sarilumab for rheumatoid arthritis. These drugs could give shares the shot in the arm they need. Regeneron Pharmaceuticals ( NASDAQ:REGN ) and collaboration partner Sanofi ( NYSE:SNY ) recently won Food and Drug Administration (FDA) approval for their eczema drug, Dupixent, and this week, the FDA accepted the two companies' application for approval of sarilumab, or Kevzara, a rheumatoid arthritis drug that's already gotten a regulatory green light in Canada. Can these two drugs get Regeneron's shares back to their winning ways? Given these drugs target multibillion-dollar indications, I think the answer is yes. Erasing eczema Dupixent inhibits interleukin-4 and interleukin-13, two anti-inflammatory proteins that can lead to eczema, a condition that causes itchy skin lesions and other symptoms that can take a big toll on patients' quality of life.
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- Medigene AG reports Financial Results and Business Update for Q1 2024 [Yahoo! Finance]Yahoo! Finance
- INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire
- Regeneron (REGN) Reports Next Week: What You Should Expect [Yahoo! Finance]Yahoo! Finance
- UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study [Yahoo! Finance]Yahoo! Finance
- AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study [Reuters]Reuters
REGN
Earnings
- 2/2/24 - Beat
REGN
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- REGN's page on the SEC website